Abstract：
Growing evidence has shown that hypovitaminosis D is a risk factor for developing schizophrenia and comorbid conditions. Therefore, this study aimed to examine the effect of vitamin D supplementation on serum levels of vitamin D, metabolic factors related to insulin resistance (IR) and the severity of the disorder in patients with schizophrenia.
Forty-eight chronic male patients with schizophrenia with vitamin D deficiency (≤20 ng/mL= (≤50 nmol/l) were selected and randomly assigned to vitamin D treatment and placebo groups. Subjects were supplemented for 8 weeks with vitamin D (2000 IU/day) or placebo.
Within-group comparison revealed that the vitamin D group had a significant reduction in waist circumference, Positive and Negative Syndrome Scale - total score (PANSS-TS), and glycogen synthase kinase 3 beta (GSK-3β) levels (P = .022, P = <.001 and P = .013, respectively). On the other hand, the placebo group showed a significant increase in the level of fasting serum insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (P = .003 and P = .003). The between-group comparison showed a significant difference in terms of PANSS-TS, GSK-3β, fasting serum insulin (FSI), and HOMA-IR (P = .022, P = .048, P = .013 and P = .014 respectively).
Among vitamin D deficient patients with schizophrenia, vitamin D supplementation may affect GSK-3 β, an important biomarker in schizophrenia and insulin resistance. In addition, vitamin D supplementation in such patients may reduce the disorder\'s symptom severity.
Forty-eight chronic male patients with schizophrenia with vitamin D deficiency (≤20 ng/mL= (≤50 nmol/l) were selected and randomly assigned to vitamin D treatment and placebo groups. Subjects were supplemented for 8 weeks with vitamin D (2000 IU/day) or placebo.
Within-group comparison revealed that the vitamin D group had a significant reduction in waist circumference, Positive and Negative Syndrome Scale - total score (PANSS-TS), and glycogen synthase kinase 3 beta (GSK-3β) levels (P = .022, P = <.001 and P = .013, respectively). On the other hand, the placebo group showed a significant increase in the level of fasting serum insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (P = .003 and P = .003). The between-group comparison showed a significant difference in terms of PANSS-TS, GSK-3β, fasting serum insulin (FSI), and HOMA-IR (P = .022, P = .048, P = .013 and P = .014 respectively).
Among vitamin D deficient patients with schizophrenia, vitamin D supplementation may affect GSK-3 β, an important biomarker in schizophrenia and insulin resistance. In addition, vitamin D supplementation in such patients may reduce the disorder\'s symptom severity.
摘要：
背景：越来越多的证据表明维生素D缺乏症是发生精神分裂症和合并症的危险因素。因此,这项研究旨在研究补充维生素D对血清维生素D水平的影响，与精神分裂症患者胰岛素抵抗（IR）和疾病严重程度相关的代谢因素。
方法：选择48例伴维生素D缺乏（≤20ng/mL=（≤50nmol/l）的精神分裂症慢性男性患者，随机分为维生素D治疗组和安慰剂组。受试者补充维生素D（2000IU/天）和安慰剂8周，分别。
结果：组内比较显示，维生素D组腰围明显减少，阳性和阴性综合征量表-总分（PANSS-TS）和，糖原合成酶激酶3β(GSK-3β)水平(分别为P=.022,P=<.001和P=.013)。另一方面,安慰剂组的空腹血清胰岛素水平和胰岛素抵抗稳态模型评估(HOMA-IR)水平显著升高(P=.003和P=.003).组间比较显示在PANSS-TS方面有显著差异，GSK-3β,空腹血清胰岛素（FSI）和HOMA-IR（分别为P=.022，P=.048，P=.013和P=.014）。
结论：在缺乏维生素D的精神分裂症患者中，补充维生素D可能会影响GSK-3β，精神分裂症和胰岛素抵抗的重要生物标志物。此外,此类患者补充维生素D可能会减轻症状严重程度。
方法：选择48例伴维生素D缺乏（≤20ng/mL=（≤50nmol/l）的精神分裂症慢性男性患者，随机分为维生素D治疗组和安慰剂组。受试者补充维生素D（2000IU/天）和安慰剂8周，分别。
结果：组内比较显示，维生素D组腰围明显减少，阳性和阴性综合征量表-总分（PANSS-TS）和，糖原合成酶激酶3β(GSK-3β)水平(分别为P=.022,P=<.001和P=.013)。另一方面,安慰剂组的空腹血清胰岛素水平和胰岛素抵抗稳态模型评估(HOMA-IR)水平显著升高(P=.003和P=.003).组间比较显示在PANSS-TS方面有显著差异，GSK-3β,空腹血清胰岛素（FSI）和HOMA-IR（分别为P=.022，P=.048，P=.013和P=.014）。
结论：在缺乏维生素D的精神分裂症患者中，补充维生素D可能会影响GSK-3β，精神分裂症和胰岛素抵抗的重要生物标志物。此外,此类患者补充维生素D可能会减轻症状严重程度。
